Form 8 (OPD) - Redx Pharma Plc

RNS Number : 4644S

Redx Pharma plc

09 March 2023

 

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

1.  KEY INFORMATION

(a) Full name of discloser:	Redx Pharma plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.	N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree	Redx Pharma plc
(d) Is the discloser the offeror or the offeree?	Offeree
(e) Date position held:   The latest practicable date prior to the disclosure	7 March 2023
(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?   If it is a cash offer or possible cash offer, state "N/A"	Yes - Jounce Therapeutics, Inc.

2.  POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)  Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:	Redx Ordinary shares of £0.01 each
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	0	-	0	-
(2) Cash-settled derivatives:	0	-	0	-
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	0	-	0	-
TOTAL:	0	-	0	-

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b)  Rights to subscribe for new securities

Class of relevant security in relation to which subscription right exists:	N/A
Details, including nature of the rights concerned and relevant percentages:	N/A

3.  POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

(a) Interests held by the directors of Redx Pharma plc, their close relatives and related trusts Name Class Number of Shares Percentage shareholding (%) Lisa Mary Whewell Anson Ordinary 163,183 0.04872 Jane Griffiths Ordinary 84,746 0.02530 Sarah Lucinda Gordon Wild Ordinary 1,316,587 0.39311 Peter Eric Presland Ordinary 146,225 0.04366 (b) Interests held as options or awards under the share plans of Redx Pharma plc by the directors of Redx Pharma plc and their close relatives and related trusts who are not exempt principal traders for the purposes of Rule 8 of the Code Name Share Plan No. of ordinary shares under option Date of grant Vesting date Expiry date Exercise price per share (p) Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-21 1-Jul-30 15.5 Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-22 1-Jul-30 15.5 Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 1-Jul-20 1-Jul-23 1-Jul-30 15.5 Lisa Mary Whewell Anson 2020 all employee share option scheme 5,300,000 1-Jul-20 1-Jul-23 1-Jul-30 15.5 Lisa Mary Whewell Anson 2020 all employee share option scheme 451,145 2-Dec-20 2-Dec-21 2-Dec-30 56.0 Lisa Mary Whewell Anson 2020 all employee share option scheme 451,145 2-Dec-20 2-Dec-22 2-Dec-30 56.0 Lisa Mary Whewell Anson 2020 all employee share option scheme 451,144 2-Dec-20 2-Dec-23 2-Dec-30 56.0 Lisa Mary Whewell Anson 2020 all employee share option scheme 2,030,152 2-Dec-20 2-Dec-23 2-Dec-30 56.0 Lisa Mary Whewell Anson 2020 all employee share option scheme 1,000,000 19-May-22 19-May-25 19-May-32 59.0 Lisa Mary Whewell Anson 2020 all employee share option scheme 1,700,000 21-Dec-22 21-Dec-25 21-Dec-32 56.5 Peter Eric Presland 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5 Peter Eric Presland 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5 Peter Eric Presland 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5 Bernhard Kirschbaum 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5 Bernhard Kirschbaum 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5 Bernhard Kirschbaum 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5 Sarah Lucinda Gordon Wild 2021 Director share option plan 66,666 1-Jul-21 1-Jul-22 1-Jul-31 61.5 Sarah Lucinda Gordon Wild 2021 Director share option plan 66,667 1-Jul-21 1-Jul-23 1-Jul-31 61.5 Sarah Lucinda Gordon Wild 2021 Director share option plan 66,667 1-Jul-21 1-Jul-24 1-Jul-31 61.5 Dr. Jane Veronica Griffiths 2021 Director share option plan 133,333 28-Jan-22 28-Jan-23 28-Jan-32 81.0 Dr. Jane Veronica Griffiths 2021 Director share option plan 133,333 28-Jan-22 28-Jan-24 28-Jan-32 81.0 Dr. Jane Veronica Griffiths 2021 Director share option plan 133,334 28-Jan-22 28-Jan-25 28-Jan-32 81.0 Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,666 28-Jan-22 28-Jan-23 28-Jan-32 81.0 Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,667 28-Jan-22 28-Jan-24 28-Jan-32 81.0 Dr. Robert Andrew Donald Scott 2021 Director share option plan 66,667 28-Jan-22 28-Jan-25 28-Jan-32 81.0 (c) Interests and short positions held by investment managers, investment advisers and connected advisors of Redx Pharma plc Registered holder Class Number of Shares Percentage shareholding (%) WG Partners LLP Ordinary 114,593 0.03422 (d) Interests held by other presumed concert parties of Redx Pharma plc Registered holder Class Number of Shares Percentage shareholding (%) RM Special Holdings 3, LLC  Ordinary 217,880,610 65.05618 RedCo II Master Fund, L.P. Ordinary 27,461,017 8.199486 Redmile Group, LLC (" Redmile ") is the investment manager of RedCo II Master Fund, L.P. Redmile is also the investment manager of the funds that own RM Special Holdings 3, LLC. (e) Rights to subscribe for new securities held by other presumed concert parties of Redx Pharma plc Registered holder Class of relevant security Product description Due date Principal amount outstanding Conversion price Number of Ordinary Shares  on conversion RM Special Holdings 3, LLC  Ordinary Shares Convertible loan notes issued by Redx Pharma plc pursuant to the terms of the note purchase agreement dated 29 June 2020 (" NPA "), convertible into Ordinary Shares of Redx Pharma plc 4 August 2023 (unless extended in accordance with the terms of the NPA) £11,200,026.81 £0.155 per Ordinary Share 72,258,237

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4. OTHER INFORMATION

(a)  Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"

None

(c)  Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	No
Supplemental Form 8 (SBL)	No

Date of disclosure:	9 March 2023
Contact name:	Claire Solk, Group Company Secretary
Telephone number:	[phone]

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on [phone].

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

 

END

 

 

FEEFKLFBXXLFBBX